Join the club for FREE to access the whole archive and other member benefits.

Mark Allen

Co-Founder and CEO at Elevian

Dr. Allen is a serial entrepreneur and executive, with experience leading organizations from inception to profitable growth to successful exit.

Dr. Allen has a BS in Applied Physics from Columbia University and an MD from UCLA.

During his medical training, he developed one of the first web-based clinical decision support systems to guide ER physicians to make the right patient care decisions. Dr. Allen founded Corticon to bring this new technology to market. Under Dr. Allen’s leadership as CEO, Corticon became one of the leading commercial rules engine software products, powering automated decision-making in healthcare, insurance, banking, retail and manufacturing.

In early 2017, excited by the recent scientific progress in the longevity industry, Dr. Allen left Progress with a passion to extend healthy lifespan.

He partnered with Elevian’s scientific co-founders at Harvard to develop their GDF11 technology into new drugs, recruiting and leading a team of leading scientists and drug development veterans. An active member of YPO since 2009, Dr. Allen serves on the board of YPO San Francisco Gold.

Visit website: https://www.elevian.com/mark-allen

 markallenmd

See also: Company Elevian - Young blood medicine maker for body rejuvenation.

Details last updated 25-Nov-2020

Mark Allen News

Reason reports back from October's Rejuvenation Startup Summit

Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials

Elevian has secured $40 million for anti-aging diseases and heart stroke

Elevian has secured $40 million for anti-aging diseases and heart stroke

FierceBiotech - 17-Sep-2021

$40 million for clinical research, lead program-stroke recovery focuses GDF11

Elevian raises $15M in preclinical work towards clinical antiaging

Elevian raises $15M in preclinical work towards clinical antiaging

FierceBiotech - 24-Nov-2020

rGDF11 in clinic targets multiple age related disease therapies